On the subject in the title: Second pass at: Reimbursement variation across member states Working notes rather than a conclusion.
The question about Reimbursement variation across member states that I actually want answered is the second one below. The first is context and I have kept it short.
Both are stated with units, and I have said what I already checked so that nobody repeats it.
Spain: AEMPS is the regulator. Public reimbursement for weight management has been limited with regional variation in specialist pathways. Private prescription is common.
A single observation, in a thread that deserves better than single observations.
This follows post #2 rather than contradicting it.
Reimbursement varies substantially by member state. Some (Germany, France, Netherlands) restrict weight-management coverage. Others are more permissive. That variation is the single most determinative factor in access for most EU residents.
Worth separating two things that the opening post runs together.
Private prescription with self-payment is legal across the EU and is the common route where public reimbursement is not available.
Bookmarking this. I will come back when I have something worth adding.
My understanding of Reimbursement variation across member states is a few years old and may have been superseded. If it has been, I would genuinely like to know rather than keep repeating it.
On post #4 — agreed on the reasoning, with one qualification.
An observation about Reimbursement variation across member states that I cannot explain and am posting anyway, on the principle that unexplained observations are more useful public than private.
Post #6 is the version of this I will quote in future. One addition.
Movement of medicines between member states for personal use has rules, and they are published rather than a matter of custom.
Where I part company with post #8, and it is a narrow parting.
Reframing Reimbursement variation across member states slightly, because I think the disagreement is about the question rather than the answer. If the question is "does it happen", yes. If it is "how often", nobody here knows.
The public assessment report published at authorisation is one of the best free technical documents available on any of these compounds and it is rarely cited here.
That much is documented. The rest is how I have interpreted it.
Posting my Reimbursement variation across member states numbers with the method attached so they can be discounted properly. Uncontrolled, unblinded, and collected by someone who wanted a particular answer.
Agreed, and I will stop repeating the version of this I had been repeating.
Confirming post #11 from a second method, which matters more than confirming it from a second person.
What I want from this Reimbursement variation across member states thread is the list of things that would need to be true for the claim to hold. If we can write that list, we can check it.
France: ANSM implements EU framework. Reimbursement has been narrower for weight management. Prescribing restrictions were applied during shortages, directing available product toward diabetes indications.
Anyone quoting an eligibility threshold should cite the national document, because thresholds differ between states and have changed within them.
Where I part company with post #15, and it is a narrow parting.
I have been on both sides of the Reimbursement variation across member states argument in this category within eighteen months, which should tell you how strong the evidence for either side is.
Post #15 is the version of this I will quote in future. One addition.
One caution on Reimbursement variation across member states: everything above assumes the underlying documentation is what it claims to be. That assumption is doing real work and is rarely stated.
Post #15 and I disagree about the size of the effect, not about the direction.
Pharmacy dispensing practice varies within a member state as well as between them, which is why first-hand accounts diverge honestly.
Where the Reimbursement variation across member states discussion usually stalls is that nobody wants to say "I do not know" and everyone is willing to say "it varies". Those are the same sentence with different clothes on.
Post #22 and I disagree about the size of the effect, not about the direction.
Italy: AIFA controls reimbursement through a note system. Weight-management indications have not attracted public reimbursement. Regional health authorities add further variation.
Reporting the observation and leaving the explanation open deliberately.
The arithmetic in post #24 is right; the assumption feeding it is the part to check.
The bit of Reimbursement variation across member states that nobody enjoys is that the answer changes depending on what you are trying to decide with it. Say what the decision is and the thread will converge.
Cost comparisons across member states should state what is included, because the components bundled into a price differ.
I have deliberately not rounded that, because the rounding is where the argument starts.
Post #26 put the caveat in the right place and I want to underline it.
Second-hand on Reimbursement variation across member states, so weight it accordingly — someone whose method I trust told me this and I have not verified it myself.
Post #27 is right about the mechanism and I think understates the practical bit.
Say which member state. A statement true in one is regularly false in another and the difference is not marginal.
Old habit: I write down the expected answer before I calculate it.
| Topic | Participants | Replies | Views | Activity |
|---|---|---|---|---|
|
EMA product information as a primary source
Posting this under the heading it deserves: EMA product information as a primary source Everything below is what sits behind that. Something about EMA product information does not reconcile and I would like a…
|
+70 | 74 | 7k | 8mo |
|
German, French and Dutch differences, compared
German, French and Dutch differences, compared — setting out what I have, and where I think it stops being reliable. Asking about german directly, because I have read four threads on it and each answered a…
|
2 | 12k | 10h | |
|
Cross-border purchase rules within the EU
On the subject in the title: Cross-border purchase rules within the EU Working notes rather than a conclusion. The question about cross-border purchase rules within that I actually want answered is the second…
|
+45 | 49 | 15k | 8mo |
|
EMA product information as a primary source — does this still hold?
The question in the title: EMA product information as a primary source — does this still hold? I will give what I have already checked below so nobody repeats it. Something about EMA product information does…
|
+127 | 150 | 41k | 20mo |
|
Revisiting: German, French and Dutch differences, compared
Posting this under the heading it deserves: Revisiting: German, French and Dutch differences, compared Everything below is what sits behind that. I have spent a fortnight trying to pin German down and I want…
|
+90 | 99 | 32k | 9mo |
| Topic | Participants | Replies | Views | Activity |
|---|---|---|---|---|
|
Prescription requirements and telehealth models — a second dataset
On the subject in the title: Prescription requirements and telehealth models — a second dataset Working notes rather than a conclusion. Posting a small dataset on Prescription requirements and telehealth…
|
+87 | 94 | 1.1k | 21d |
|
Tracking a shortage from primary sources rather than rumour — the long version
On the subject in the title: Tracking a shortage from primary sources rather than rumour — the long version Working notes rather than a conclusion. Tracking a shortage keeps being re-asked here and I think…
|
2 | 60 | 1d | |
|
Price changes over 2025 and 2026, tabulated and dated — does this still hold?
Price changes over 2025 and 2026, tabulated and dated — does this still hold? I have a specific reason for asking rather than idle curiosity, and the context is below. Documenting an access outcome, dated,…
|
+147 | 156 | 18k | 3mo |
|
Reimbursement variation across member states
Reimbursement variation across member states Writing it up because I had to work it out twice and would rather nobody else did. Asking about reimbursement variation across member states directly, because I…
|
+7 | 11 | 39k | 3mo |
|
Managing an unplanned gap in supply — what changed since
On the subject in the title: Managing an unplanned gap in supply — what changed since Working notes rather than a conclusion. What changes if the standard account of Managing an unplanned gap is wrong? I ask…
|
+114 | 124 | 54k | 8mo |